Apart from its positives and negatives, MSD (known as Merck in the U.S.) is a company apt at ‘adaptation.’

MSD, which first cut its appearance in circulatory, respiratory drugs, and vaccines, became a leader in the field of diabetes in the 2000s with the introduction of its Januvia(sitagliptin), a DPP-4 inhibitor. In 2010, MSD became a sensation with the release of its PD-1 inhibitor ‘Keytruda(pembrolizumab),’ marking the start of the era of cancer immunotherapies.

MSD’s forward-looking eye that allowed for the launch and success of various first-in-class drugs regardless of the disease area, is an undeniable strength of MSD.

However, MSD had also been in the throes o